Explore more press releases
Topics
Period
recent search
Showing: 1 – 05 of 236 Press Releases
27 February 2026
27 February 2026
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
PARIS, FRANCE, 27 FEBRUARY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional marketing authorization of…
12 February 2026
12 February 2026
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
PARIS, FRANCE, 12 February 2026 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year (FY) 2025 and for the fourth quarter of 2025.
29 January 2026
29 January 2026
Ipsen nominates Peter Guenter to its Board of Directors
PARIS, FRANCE, 29 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position.
27 January 2026
27 January 2026
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
PARIS, FRANCE, 27 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026. Pierrick will succeed Aidan…
21 January 2026
21 January 2026
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration…
